Trial reportLeukemia2007
Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group.
Trial report in Leukemia, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00880243 (Effect of Priming With Granulocyte-Macrophage Colony-Stimulating Factor During Chemotherapy and Comparison of Timed Sequential Chemotherapy vs 4 Courses of High Dose Cytarabine as Consolidation in Younger Adults With Newly Diagnosed AML), which is not on this map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Priming With Granulocyte-Macrophage Colony-Stimulating Factor During Chemotherapy and Comparison of Timed Sequential Chemotherapy vs 4 Courses of High Dose Cytarabine as Consolidation in Younger Adults With Newly Diagnosed AML
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia.The Cochrane database of systematic reviews · 2012Pooled it
- Pooled it
- Evaluation of allogeneic hematopoietic SCT in younger adults with adverse karyotype AML.Bone marrow transplantation · 2012Trial
- Acupuncture for chemotherapy-induced neutropenia in patients with gynecologic malignancies: a pilot randomized, sham-controlled clinical trial.Journal of alternative and complementary medicine (New York, N.Y.) · 2009Trial
- Review
- Comprehensive mutational profiling and clinical outcome of adult acute myeloid leukemia patients with NUP98 rearrangement.Leukemia · 2026Article
- Mathematical modeling of the impact of cytokine response of acute myeloid leukemia cells on patient prognosis.Scientific reports · 2018Article
- Adaptive Interventions and SMART Designs: Application to child behavior research in a community setting.The American journal of evaluation · 2016Article
- [Haploidentical transplantation for the treatment of intermediate- or high- risk acute myeloid leukemia in first complete remission: guideline and practice].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2016Article
- Are there any new insights for G-CSF and/or AMD3100 in chemotherapy of haematological malignants?Medical oncology (Northwood, London, England) · 2015Review
- SMART designs in cancer research: Past, present, and future.Clinical trials (London, England) · 2014Article
- Article
- The hematopoietic stem cell niche.Frontiers in bioscience (Landmark edition) · 2012Review
- Wilms' tumor 1 single-nucleotide polymorphism rs16754 does not predict clinical outcome in adult acute myeloid leukemia.Leukemia · 2011Article
- Impact of invasive fungal disease on the chemotherapy schedule and event-free survival in acute leukemia patients who survived fungal disease: a case-control study.Haematologica · 2011Article
- Immune-based therapeutics for pediatric cancer.Expert opinion on biological therapy · 2010Review
- Targeting leukemia stem cells: The new goal of therapy in adult acute myeloid leukemia.World journal of stem cells · 2009Article
- The role of timed sequential chemotherapy in adult acute myelogenous leukemia.Current hematologic malignancy reports · 2008Review
- Recurrent in-frame insertion in C/EBPalpha TAD2 region is a polymorphism without prognostic value in AML.Leukemia · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In a multicenter trial, 259 young adults (15-49 years) with newly diagnosed acute myeloid leukemia (AML) were first randomized to receive a timed-sequential induction regimen given either alone (135 patients) or concomitantly with granulocyte-macrophage colony-stimulating factor (GM-CSF) (124 patients). Patients reaching complete remission (CR) were then randomized to compare a timed-sequential consolidation to a postremission chemotherapy including four cycles of high-dose cytarabine followed by maintenance courses. In the appropriate arm, GM-CSF was given concurrently with chemotherapy during all cycles of consolidation. CR rates were significantly better in the GM-CSF arm (88 vs 78%, P<0.04), but did not differ after salvage. Patients receiving GM-CSF had a higher 3-year event-free survival (EFS) estimate (42 vs 34%), but GM-CSF did not impact on overall survival. Patients with intermediate-risk cytogenetics benefited more from GM-CSF therapy (P=0.05) in terms of EFS than patients with other cytogenetics. This was also confirmed when considering only patients following the second randomization, or subgroups defined by a prognostic index based on cytogenetics and the number of courses required for achieving CR. Priming of leukemic cells with hematopoietic growth factors is a means of enhancing the efficacy of chemotherapy in younger adults with AML.
Indexed as
Identifiers
17252021What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.